In February of 2024, we published our 2024 Oncology Market Outlook. In that paper, we made four broad predictions:

  1. KRAS will kick into high gear.
  2. CAR-Ts will focus on manufacturing and the move to outpatient treatment.
  3. Targeted protein degradation will finally “arrive.”
  4. Radiopharmaceuticals will grow further, with expanded emphasis on alpha emitters.

Now, 12 months later, we revisit each of those predictions to see how well we did.